Blood Cancer News and Research

RSS

Mechanism of Cancer Drug Targeting Tumor Suppressor Genes Unveiled

Researchers have revealed the mechanism of a drug shown to be effective in treating certain types of cancer, which targets a protein modification silencing the expression of multiple tumor suppressor genes.

22 Feb 2024

Understanding How Inherited DNA Variations Influence Blood Cancer Development

Large-scale genetic analysis has helped researchers uncover the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer.

18 Jan 2024

Study Elucidates How Mutant NPM1 Protein Drives Leukemia by Activating Autophagy System

In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML.

5 Dec 2023

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification.

28 Aug 2023

New Culture System may Improve Efficiency and Safety of Genome Editing in HSCs

Hematopoietic stem cells (HSCs) are rare cells found in the bone marrow that produce red blood cells, white blood cells, and platelets.

11 Jul 2023

Scientists Engineer the First CRISPR-Based Drug Candidate to Directly Target E. Coli

Many people have experienced infections from E. coli, which are primarily seen as inconvenient and unpleasant.

10 May 2023

High-Throughput Screening of Existing Drugs to Fight Multiple Myeloma More Effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells.

28 Apr 2023

New Technique Identifies a Gene that Drives Clonal Expansion of Abnormal Cells

An international coalition of biomedical researchers co-led by Alexander Bick, MD, PhD, at Vanderbilt University Medical Center has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients' risk of blood cancer.

12 Apr 2023

New Epigenetic Vulnerability Of Acute Myeloid Leukemia Revealed

Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ways to treat AML, while preserving normal blood development.

10 Apr 2023

COVID-19 vaccines boost the levels of T cells in immunocompromised hematology patients

Researchers found that, despite being heavily immunocompromised, hematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.

30 Mar 2023

Stem cells must take out the trash to protect against age-related diseases

In humanity's ongoing quest for the elixir of life, the science keeps pointing to stem cells. Research increasingly shows that maintaining stem cell fitness promotes a long healthspan, and new findings show keeping stem cells clean and tidy is an integral step.

22 Mar 2023

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Pediatric acute myeloid leukemia or pAML is a childhood blood cancer, one that has proved confounding to clinicians and researchers, with a high relapse rate and relatively few identified genetic mutations (compared to the adult version) that might explain its cause.

8 Mar 2023

Whole genome sequencing might help better assess tumor evolution

To develop the most efficacious, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, researchers and clinicians must first understand the genetic changes that cause cancer to develop.

23 Feb 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Analyzing the immune microenvironment around Hodgkin lymphoma tumors

The most detailed study of Hodgkin lymphoma, a type of blood cancer, has offered considerable insight into what tumor cells must do to sustain. The Wellcome Sanger Institute discovered that cancer cells utilize signals to attract specific types of immune cells and direct them not to attack.

15 Feb 2023

Treating ovarian cancer with immunotherapy involving CAR T cells

Recent research revealed that CAR T-cell therapy, a particular type of cancer treatment in which the immune system’s T cells are directed to kill tumor cells, is successful in treating ovarian cancer in mice.

7 Feb 2023

CAR T-cell therapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022

UC San Diego Alpha Clinic awarded $8 million to bring new stem cell-based therapies to patients

Stem cells show particular promise in treating diseases for which few other effective treatments exist.

25 Nov 2022

Pioneering gene editing approach could lead to new treatments for CTLA-4 insufficiency

A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.

From University College London 27 Oct 2022